April 24, 2007 - Company Release
Forest Laboratories, Inc. Reports Fiscal Year 2007 Fourth Quarter Revenues of $885,000,000, Reported EPS Loss of ($0.75) and Adjusted EPS of $0.74*, Excluding the Effect of the Cerexa Acquisition
January 11, 2007 - Company Release
Forest Laboratories Announces Completion of Acquisition of Cerexa, Inc.
December 14, 2006 - Company Release
Forest Laboratories Announces Acquisition of Cerexa, Inc.
November 6, 2006 - Company Release
Cerexa to Present at Rodman & Renshaw Healthcare Conference
November 1, 2006 - Company Release
Cerexa Expands Portfolio of Novel Anti-Infective Therapies
Through In-Licensing Agreement with Meiji Seika Kaisha
October 16, 2006 - Company Release
Cerexa to Present at BIO InvestorForum 2006
September 29, 2006 - Company Release
Phase 2 Study Shows Ceftaroline Highly Efficacious in Treatment of cSSSI Compared to Standard Therapy
September 9, 2006 - Company Release
Cerexa to Present at Credit Suisse Biotechnology Conference
August 2, 2006 - Company Release
Cerexa Reports Positive Top-Line Results for Phase 2 Clinical Trial of Ceftaroline
April 5, 2006 - Company Release
Cerexa Announces Completion of Enrollment in Ceftaroline Phase 2 Trial
March 28, 2006 - Company Release
Cerexa to Present at Future Leaders Conference
March 14, 2006 - Company Release
FDA Grants Cerexa Fast Track Designation for PPI-0903
November 15, 2005 - Company Release
Cerexa to Present at Credit Suisse First Boston Healthcare Conference
November 7, 2005 - Company Release
Cerexa to Present at Rodman & Renshaw Healthcare Conference
October 19, 2005 - Company Release
Cerexa, Inc. Initiates Phase 2 Clinical Trial of PPI-0903
August 23, 2005 - Company Release
Cerexa, Inc. Announces Corporate Launch and $50 Million Initial Financing